XP-105 is under clinical development by Xynomic Pharmaceuticals and currently in Phase II for Breast Cancer. According to GlobalData, Phase II drugs for Breast Cancer have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how XP-105’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
XP-105 overview
XP-105 (BI-860585) is under development for the treatment of advanced and metastatic solid tumor including breast cancer. It is administered orally. The drug candidate targets selective ATP-competitive mTORC1 and mTORC2 serine/threonine kinase that exert a more sustained inhibition of the PI3K/AKT/mTOR pathway. The drug candidate is a new chemical entity (NCE).
Xynomic Pharmaceuticals overview
Xynomic Pharmaceuticals (Xynomic Pharmaceuticals Holdings) develops and sells innovative small molecule drugs for the treatment of cancer across various patients. The company is headquartered in Shanghai, China.
For a complete picture of XP-105’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
